{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:53:51Z","timestamp":1791359631028,"version":"4.3.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000749"],"award-info":[{"award-number":["82000749"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04780-8","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:43:38Z","timestamp":1791359018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Activator of Sirt6 exerts antitumor activity in pituitary neuroendocrine tumors"],"prefix":"10.1007","volume":"91","author":[{"given":"Hong","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiting","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe Bao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"1","key":"4780_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"S.L. Asa, O. Mete, A. Perry, R.Y. Osamura, Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr. Pathol. 33(1), 6\u201326 (2022). https:\/\/doi.org\/10.1007\/s12022-022-09703-7","journal-title":"Endocr. Pathol."},{"issue":"10","key":"4780_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1056\/NEJMra1810772","volume":"382","author":"S Melmed","year":"2020","unstructured":"S. Melmed, Pituitary-Tumor Endocrinopathies, N Engl. J. Med. 382(10), 937\u2013950 (2020). https:\/\/doi.org\/10.1056\/NEJMra1810772","journal-title":"N Engl. J. Med."},{"issue":"6","key":"4780_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1159\/000504000","volume":"110","author":"S Lin","year":"2020","unstructured":"S. Lin, A. Zhang, X. Zhang, Z.B. Wu, Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications. Neuroendocrinology. 110(6), 477\u2013488 (2020). https:\/\/doi.org\/10.1159\/000504000","journal-title":"Neuroendocrinology"},{"issue":"6771","key":"4780_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35001622","volume":"403","author":"S Imai","year":"2000","unstructured":"S. Imai, C.M. Armstrong, M. Kaeberlein, L. Guarente, Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 403(6771), 795\u2013800 (2000). https:\/\/doi.org\/10.1038\/35001622","journal-title":"Nature"},{"issue":"6","key":"4780_CR5","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.14336\/AD.2022.0413","volume":"13","author":"Z Guo","year":"2022","unstructured":"Z. Guo, P. Li, J. Ge, H. Li, SIRT6 in Aging, Metabolism, Inflammation and Cardiovascular Diseases. Aging Dis. 13(6), 1787\u20131822 (2022). https:\/\/doi.org\/10.14336\/AD.2022.0413","journal-title":"Aging Dis."},{"key":"4780_CR6","doi-asserted-by":"publisher","first-page":"861334","DOI":"10.3389\/fonc.2022.861334","volume":"12","author":"Y Li","year":"2022","unstructured":"Y. Li, J. Jin, Y. Wang, SIRT6 Widely Regulates Aging, Immunity, and Cancer. Front. Oncol. 12, 861334 (2022). https:\/\/doi.org\/10.3389\/fonc.2022.861334","journal-title":"Front. Oncol."},{"issue":"11","key":"4780_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-023-00883-8","volume":"19","author":"KKY Ho","year":"2023","unstructured":"K.K.Y. Ho, U.B. Kaiser, P. Chanson, M. Gadelha, J. Wass, L. Nieman et al., Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification. Nat. Rev. Endocrinol. 19(11), 671\u2013678 (2023). https:\/\/doi.org\/10.1038\/s41574-023-00883-8","journal-title":"Nat. Rev. Endocrinol."},{"issue":"20","key":"4780_CR8","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1158\/0008-5472.CAN-14-1308","volume":"74","author":"M Ming","year":"2014","unstructured":"M. Ming, W. Han, B. Zhao, N.R. Sundaresan, C.X. Deng, M.P. Gupta et al., SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer. Cancer Res. 74(20), 5925\u20135933 (2014). https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1308","journal-title":"Cancer Res."},{"issue":"6","key":"4780_CR9","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.cell.2012.10.047","volume":"151","author":"C Sebastian","year":"2012","unstructured":"C. Sebastian, B.M. Zwaans, D.M. Silberman, M. Gymrek, A. Goren, L. Zhong et al., The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell. 151(6), 1185\u20131199 (2012). https:\/\/doi.org\/10.1016\/j.cell.2012.10.047","journal-title":"Cell"},{"key":"4780_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.biopha.2018.06.070","volume":"106","author":"J Tian","year":"2018","unstructured":"J. Tian, L. Yuan, Sirtuin 6 inhibits colon cancer progression by modulating PTEN\/AKT signaling. Biomed. Pharmacother. 106, 109\u2013116 (2018). https:\/\/doi.org\/10.1016\/j.biopha.2018.06.070","journal-title":"Biomed. Pharmacother"},{"issue":"9","key":"4780_CR11","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1182\/blood-2015-06-649970","volume":"127","author":"M Cea","year":"2016","unstructured":"M. Cea, A. Cagnetta, S. Adamia, C. Acharya, Y.T. Tai, M. Fulciniti et al., Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 127(9), 1138\u20131150 (2016). https:\/\/doi.org\/10.1182\/blood-2015-06-649970","journal-title":"Blood"},{"issue":"6","key":"4780_CR12","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.cell.2016.04.033","volume":"165","author":"S Kugel","year":"2016","unstructured":"S. Kugel, C. Sebastian, J. Fitamant, K.N. Ross, S.K. Saha, E. Jain et al., SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Cell. 165(6), 1401\u20131415 (2016). https:\/\/doi.org\/10.1016\/j.cell.2016.04.033","journal-title":"Cell"},{"issue":"3","key":"4780_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/hep.26413","volume":"58","author":"JU Marquardt","year":"2013","unstructured":"J.U. Marquardt, K. Fischer, K. Baus, A. Kashyap, S. Ma, M. Krupp et al., Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology. 58(3), 1054\u20131064 (2013). https:\/\/doi.org\/10.1002\/hep.26413","journal-title":"Hepatology"},{"issue":"11","key":"4780_CR14","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/ncb2590","volume":"14","author":"L Min","year":"2012","unstructured":"L. Min, Y. Ji, L. Bakiri, Z. Qiu, J. Cen, X. Chen et al., Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat. Cell. Biol. 14(11), 1203\u20131211 (2012). https:\/\/doi.org\/10.1038\/ncb2590","journal-title":"Nat. Cell. Biol."},{"issue":"12","key":"4780_CR15","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/s41589-018-0150-0","volume":"14","author":"Z Huang","year":"2018","unstructured":"Z. Huang, J. Zhao, W. Deng, Y. Chen, J. Shang, K. Song et al., Identification of a cellularly active SIRT6 allosteric activator. Nat. Chem. Biol. 14(12), 1118\u20131126 (2018). https:\/\/doi.org\/10.1038\/s41589-018-0150-0","journal-title":"Nat. Chem. Biol."},{"issue":"10","key":"4780_CR16","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41419-018-1065-0","volume":"9","author":"S Iachettini","year":"2018","unstructured":"S. Iachettini, D. Trisciuoglio, D. Rotili, A. Lucidi, E. Salvati, P. Zizza et al., Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. Cell. Death Dis. 9(10), 996 (2018). https:\/\/doi.org\/10.1038\/s41419-018-1065-0","journal-title":"Cell. Death Dis."},{"issue":"8","key":"4780_CR17","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1093\/neuonc\/noac053","volume":"24","author":"H Yao","year":"2022","unstructured":"H. Yao, W. Xie, Y. Dai, Y. Liu, W. Gu, J. Li et al., TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT. Neuro Oncol. 24(8), 1286\u20131297 (2022). https:\/\/doi.org\/10.1093\/neuonc\/noac053","journal-title":"Neuro Oncol."},{"issue":"3","key":"4780_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/neuonc\/noae241","volume":"27","author":"Y Liu","year":"2025","unstructured":"Y. Liu, F. Liu, C. Li, T. Zhang, T. Han, Y. Dai et al., TRIM21-mediated ubiquitination and phosphorylation of ERK1\/2 promotes cell proliferation and drug resistance in pituitary adenomas. Neuro Oncol. 27(3), 727\u2013742 (2025). https:\/\/doi.org\/10.1093\/neuonc\/noae241","journal-title":"Neuro Oncol."},{"issue":"6","key":"4780_CR19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"The Genotype-Tissue Expression (GTEx) project","year":"2013","unstructured":"The Genotype-Tissue Expression (GTEx) project, Nat. Genet. 45(6), 580\u2013585 (2013). https:\/\/doi.org\/10.1038\/ng.2653","journal-title":"Nat. Genet."},{"issue":"11","key":"4780_CR20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/cr.2016.114","volume":"26","author":"ZJ Song","year":"2016","unstructured":"Z.J. Song, Z.J. Reitman, Z.Y. Ma, J.H. Chen, Q.L. Zhang, X.F. Shou et al., The genome-wide mutational landscape of pituitary adenomas. Cell. Res. 26(11), 1255\u20131259 (2016). https:\/\/doi.org\/10.1038\/cr.2016.114","journal-title":"Cell. Res."},{"issue":"1","key":"4780_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","volume":"37","author":"M Neou","year":"2020","unstructured":"M. Neou, C. Villa, R. Armignacco, A. Jouinot, M.L. Raffin-Sanson, A. Septier et al., Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell. 37(1), 123\u2013134 (2020). e5. https:\/\/doi.org\/10.1016\/j.ccell.2019.11.002","journal-title":"Cancer Cell."},{"issue":"8","key":"4780_CR22","doi-asserted-by":"publisher","first-page":"102899","DOI":"10.1016\/j.arcmed.2023.102899","volume":"54","author":"RG Rebollar-Vega","year":"2023","unstructured":"R.G. Rebollar-Vega, J.M. Zuarth-Vazquez, L.C. Hernandez-Ramirez, Clinical Spectrum of USP8 Pathogenic Variants in Cushing\u2019s Disease. Arch. Med. Res. 54(8), 102899 (2023). https:\/\/doi.org\/10.1016\/j.arcmed.2023.102899","journal-title":"Arch. Med. Res."},{"issue":"8","key":"4780_CR23","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1080\/15548627.2017.1328347","volume":"13","author":"ZG Leng","year":"2017","unstructured":"Z.G. Leng, S.J. Lin, Z.R. Wu, Y.H. Guo, L. Cai, H.B. Shang et al., Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death. Autophagy. 13(8), 1404\u20131419 (2017). https:\/\/doi.org\/10.1080\/15548627.2017.1328347","journal-title":"Autophagy"},{"issue":"3","key":"4780_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1080\/15548627.2017.1384886","volume":"14","author":"L Wang","year":"2018","unstructured":"L. Wang, W. Guo, J. Ma, W. Dai, L. Liu, S. Guo et al., Aberrant SIRT6 expression contributes to melanoma growth: Role of the autophagy paradox and IGF-AKT signaling. Autophagy. 14(3), 518\u2013533 (2018). https:\/\/doi.org\/10.1080\/15548627.2017.1384886","journal-title":"Autophagy"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04780-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04780-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04780-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:43:39Z","timestamp":1791359019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04780-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4780"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04780-8","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"24 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The human and animal study protocols in this research were reviewed and unconditionally approved by the respective Ethics Committees of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.For the study involving human participants and clinical specimens, all procedures were conducted in strict accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The protocol titled \"Study on Precise Molecular Classification of Pituitary Adenomas\" was approved by the Clinical Trial Ethics Committee of Ruijin Hospital (Reference Number: Clinical Ethics Approval Number: (2019) No. 39). Written informed consent was obtained from all individual patients prior to tissue collection. For the in vivo animal experiments, all care, handling, and treatment protocols were performed in compliance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH). The project titled \"Identification and role of LY6A+ drug resistant cell subsets in pituitary\" was approved by the Animal Ethics Committee of Ruijin Hospital (Approval Issue Number: RJ2023009). All efforts were made to minimize animal suffering.","order":1,"name":"Ethics","label":"Ethics declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"330"}}